General literature
Structural variation in 1,019 diverse humans based on long-read sequencing

Schloissnig S., Pani S., Ebler J., Hain C., Tsapalou V., Söylev A., Hüther P., Ashraf H., Prodanov T., Asparuhova M., Magalhães H., Höps W., Sotelo-Fonseca J. E., Fitzgerald T., Santana-Garcia W., Moreira-Pinhal R., Hunt S., Pérez-Llanos F. J., Wollenweber T. E., Sivalingam S., Wieczorek D., Cáceres M., Gilissen C., Birney E., Ding Z., Jensen J. N., Podduturi N., Stutzki J., Rodriguez-Martin B., Rausch T., Marschall T., Korbel J. O.

Nature. 2025, 644(8076):442-452.

General literature
Complex I Modulator BI4500 Reduces MASH by Limiting Oxidative Stress and Reprogramming Lipid Metabolism via AMPK in MCD Rats

Di Pasqua L. G., Lotti S., Trucchi M., Palladini G., Croce A. C., Protopapa F., Feletti F., Kauschke S. G., Sun P., Vairetti M., Ferrigno A.

Antioxidants (Basel). 2026, 15(1):82.

General literature
Mapping the functional connectome of the claustrum: Noise filtering via local inhibitory circuits

Graf M., Sadeh S., Augustine G. J.

Cell Rep. 2026, 45(1):116821.

General literature
Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation

Rutkowski M. R., Stephen T. L., Svoronos N., Allegrezza M. J., Tesone A. J., Perales-Puchalt A., Brencicova E., Escovar-Fadul X., Nguyen J. M., Cadungog M. G., Zhang R., Salatino M., Tchou J., Rabinovich G. A., Conejo-Garcia J. R.

Cancer Cell. 2015, 27(1):27-40.

General literature
TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer

McGinty M. T., Putelo A. M., Kolli S. H., Feng T-Y., Dietl M. R., Hatzinger C. N., Bajgai S., Poblete M. K., Azar F. N., Mohammad A., Kumar P., Rutkowski M. R.

Cancer Immunol Res. 2025, 13(5):696-711.

General literature
TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy

Gonzalez C., Williamson S., Gammon S. T., Glazer S., Rhee J. H., Piwnica-Worms D.

Commun Biol. 2023, 6(1):31.